Overview

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Phase:
PHASE2
Details
Lead Sponsor:
Eli Lilly and Company